Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Jul 20, 2020 - P1; N=55; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Melanoma • Oncology • Prostate Cancer • Solid Tumor
|